The BIGGEST Cancer Misconceptions We Hear with Samantha Murrell & Dr. Rob Swanda. Episode 68.

In this episode of Cracking Cancer, host Dr. Kyle Concannon is joined by breast surgical oncologist Dr. Monique Gary (Dr. Mo) and Stage IV metastatic breast cancer advocate Lindsay Campbell. The panel unpacks the complex and often overwhelming world of breast cancer surgery, moving step-by-step from the initial consultation through the operating room experience to post-operative recovery. Lindsay shares her personal surgical path—navigating the emotional frustration of an 11-week scheduling delay due to tumor growth and operating room availability, which forced a pivot from a planned double mastectomy with DIEP flap reconstruction to an immediate lumpectomy. Dr. Mo demystifies surgical decision-making, explaining how tumor grade, genetic mutations (such as BRCA1/2), and hormone/HER2 status shape surgical choices. The panel also covers practical OR preparations—such as nerve blocks, pre-medication for nausea, surgical drain management, and handling "time toxicity"—offering actionable insights for patients preparing for their own surgical journeys.

In this episode of Cracking Cancer, host Dr. Kyle Concannon is joined by breast radiologist Dr. Deepa Sheth and Stage IV metastatic breast cancer advocate Lindsay Campbell. Lindsay shares her personal story of being diagnosed at age 38 after facing nearly a year of medical delays. Despite noticing visible skin dimpling and localized pain, she was repeatedly turned away because she was under the traditional screening age of 40 and lacked a felt mass due to deep chest-wall tumor placement. It was only after her father was diagnosed with breast cancer and identified as BRCA-positive that she was able to secure a diagnostic workup. Dr. Sheth and Lindsay break down the mechanics of screening versus diagnostic imaging, explaining how 2D/3D mammography, targeted ultrasound, and breast MRI function together. Dr. Sheth highlights the critical importance of free risk-assessment tools—such as the Tyrer-Cuzick model—which can identify high-risk individuals (>20% lifetime risk) who qualify for screening starting as early as age 30. The panel also tackles the federal mandate surrounding dense breast tissue, insurance coverage nuances, and why patients must trust their intuition when advocating for timely care.

In this episode of Cracking Cancer, host Dr. Kyle Concannon sits down in person with science communicator Rob Swanda, PhD, to tackle one of the most persistent and anxiety-inducing topics in oncology: Does sugar feed cancer? Rob and Kyle break down the biochemistry behind how the body processes carbohydrates, deconstruct online misconceptions, and address the real-world harm caused when cancer patients starve themselves of vital nutrition out of fear. Rob explains the Warburg Effect—a phenomenon where cancer cells preferentially use glucose via fast, anaerobic glycolysis to generate rapid cellular energy—and clarifies why cell culture findings in a Petri dish do not translate to human metabolism. Dr. Kyle discusses human glucose homeostasis, highlighting how the liver and muscles maintain steady blood sugar through gluconeogenesis and glycogen breakdown regardless of dietary intake. The hosts issue a stark warning against extreme restrictions that lead to cancer cachexia (muscle and weight wasting) and explain why, for patients without uncontrolled diabetes, enjoying food and maintaining caloric intake is far more vital than cutting out sugars.

In this episode of Cracking Cancer, science communicator Rob Swanda, PhD, is joined by glioblastoma researcher Dr. Julio Sanchez, a postdoctoral fellow at UCLA. Julio pulls back the curtain on early-stage cancer research, shedding light on the quiet, rigorous, and often high-failure world of preclinical science that takes place long before a new drug ever reaches a clinical trial. Julio details the transition from in vitro cell line work to complex in vivo mouse models, explaining why glioblastoma remains one of the most notoriously aggressive and difficult-to-treat brain cancers. He highlights his lab's recent publication in Cancer Research, which introduced next-generation, CRISPR-engineered mouse models that far better mirror human glioblastoma pathology and the tumor immune microenvironment compared to traditional cell lines developed in the 1970s. The pair also explore the rise of therapeutic mRNA vaccines and organoid platforms, and discuss why the scientific method is fundamentally a mindset built on resilience, critical thinking, and iterative problem-solving.

In this episode of Cracking Cancer, host Dr. Kyle Concannon is joined by GI medical oncologist Dr. Chris Lieu (University of Colorado Cancer Center) and Stage IV neuroendocrine rectal cancer patient advocate Bill Thach. Bill brings an incredible, rare perspective—having navigated 11 lines of therapy and participated in 5 distinct clinical trials since his diagnosis in 2018. Dr. Lieu and Bill break down why clinical trials should be viewed as proactive options starting at diagnosis rather than as "last resorts." They demystify the multi-phase clinical trial pipeline, dispel common myths around "guinea pigs" or placebo controls, and highlight how trial participants gain access to FDA-approved therapies years ahead of the public. The panel also covers the essential role of comprehensive biomarker testing in colorectal and GI cancers—such as KRAS, DLL3, ATM, and Claudin—and highlights game-changing emerging modalities like Antibody-Drug Conjugates (ADCs), Radieligand/Radiopharmaceutical therapies, and homegrown CAR-T cell trials.